BioCentury
ARTICLE | Clinical News

Cetrorelix pamoate: Phase III data

December 14, 2009 8:00 AM UTC

Top-line data from the double-blind, European Phase III Z-036 trial in 420 patients showed that cetrorelix pamoate missed the primary endpoint of absolute change in IPSS from baseline to week 52 vs. placebo. Cetrorelix pamoate also missed all secondary endpoints vs. placebo, including significant improvements in quality of life measures, maximum and mean uroflow volume and residual volume. Aeterna Zentaris said it will conduct a full analysis of the data before determining whether to continue development of the compound. Cetrorelix pamoate was well tolerated. Patients received intramuscular cetrorelix pamoate at weeks 0, 2, 26 and 28; cetrorelix pamoate at weeks 0 and 2 followed by placebo at weeks 26 and 28; or placebo at all time points. ...